About Peanut Allergy
Peanut allergy is a rapidly growing problem in Australia and around the world. About one person in every fifty is allergic to peanuts, and every year about half of these suffer a serious, potentially life-threatening reaction to peanuts that cannot be predicted or prevented. Fatalities are fortunately rare, but allergy sufferers live in constant fear of an accidental peanut encounter.
Normally, our immune system does not react to peanuts when we are exposed to them. However, in people that suffer from peanut allergy, the immune system recognises peanuts as potentially dangerous which triggers an immune response. This response can lead to a range of symptoms, from mild itchiness, rash, and gastrointestinal upset to life-threatening anaphylaxis, with swelling and blockage of the airways and critically low blood pressure.
Aravax is a clinical-stage biotechnology company developing the first safe and rapidly effective treatment for peanut allergy. Aravax is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment.
Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
Aravax’s therapy, known as PVX108 is a result of over fifteen years of scientific research carried out at Alfred Health and Monash University.
PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic reactions to peanuts. Unlike other peanut allergy immunotherapies under development, the peptides do not contain the parts of the peanut proteins that cause life-threatening anaphylactic reactions.